Compounds > n-n--n---n----tetra(1-2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1-5-10-14-tetraazatetradecane

n-n--n---n----tetra(1-2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1-5-10-14-tetraazatetradecane and Wounds--Penetrating

n-n--n---n----tetra(1-2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1-5-10-14-tetraazatetradecane has been researched along with Wounds--Penetrating* in 1 studies

Other Studies

1 other study(ies) available for n-n--n---n----tetra(1-2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1-5-10-14-tetraazatetradecane and Wounds--Penetrating

Article	Year
Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX. Radiation protection dosimetry, 2003, Volume: 105, Issue:1-4 This study aimed to assess the efficacy of 3,4,3-LI(1,2-HOPO) for reducing uranium, plutonium and americium in rats after intramuscular injection of (U-Pu)O2 particles (MOX). Sixteen rats were contaminated by intramuscular injection of a 1 mg MOX suspension and then treated daily for 7 d with LIHOPO (30 or 200 micromol kg(-1)) or DTPA (30 micromol kg(-1)). LIHOPO was inefficient for removing Pu, Am and U from the wound site. However, it reduced Pu retention in carcass and liver by factors of 2 and 6 respectively, and Am retention in carcass and liver by factors of 10 and 30. In contrast, the effect of LIHOPO on U was to decrease the retention in kidneys by a factor of 75. These results confirm that LIHOPO is a good candidate for use after contamination with MOX, in combination with localised wound lavage or surgical treatment aimed at removing most of the contaminant at the wound site. Topics: Americium; Animals; Aza Compounds; Chelating Agents; Chelation Therapy; Decontamination; Female; Injections, Intramuscular; Organ Specificity; Oxides; Plutonium; Powders; Pyridones; Radiation Injuries; Rats; Treatment Outcome; Uranium Compounds; Whole-Body Counting; Wounds, Penetrating	2003

Article

Year

Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX.

Radiation protection dosimetry, 2003, Volume: 105, Issue:1-4

This study aimed to assess the efficacy of 3,4,3-LI(1,2-HOPO) for reducing uranium, plutonium and americium in rats after intramuscular injection of (U-Pu)O2 particles (MOX). Sixteen rats were contaminated by intramuscular injection of a 1 mg MOX suspension and then treated daily for 7 d with LIHOPO (30 or 200 micromol kg(-1)) or DTPA (30 micromol kg(-1)). LIHOPO was inefficient for removing Pu, Am and U from the wound site. However, it reduced Pu retention in carcass and liver by factors of 2 and 6 respectively, and Am retention in carcass and liver by factors of 10 and 30. In contrast, the effect of LIHOPO on U was to decrease the retention in kidneys by a factor of 75. These results confirm that LIHOPO is a good candidate for use after contamination with MOX, in combination with localised wound lavage or surgical treatment aimed at removing most of the contaminant at the wound site.

Topics: Americium; Animals; Aza Compounds; Chelating Agents; Chelation Therapy; Decontamination; Female; Injections, Intramuscular; Organ Specificity; Oxides; Plutonium; Powders; Pyridones; Radiation Injuries; Rats; Treatment Outcome; Uranium Compounds; Whole-Body Counting; Wounds, Penetrating

2003